טוען...
Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in pre-clinical leukemia models
PURPOSE: to characterize the prevalence of hypoxia in the leukemic bone marrow (BM), its association with metabolic and transcriptional changes in the leukemic blasts and the utility of hypoxia activated prodrug TH-302 in leukemia models. EXPERIMENTAL DESIGN: hyperpolarized magnetic resonance spectr...
שמור ב:
| הוצא לאור ב: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4818660/ https://ncbi.nlm.nih.gov/pubmed/26603259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3378 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|